731851-41-5

Basic information

• Product Name: 1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[(4-bromophenyl)methyl]-2-butyl-
• CAS NO: 731851-41-5
• Molecular Formula: C18H23BrN2O
• Molecular Weight: 363.297
• Mol File: 731851-41-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[(4-bromophenyl)methyl]-2-butyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[(4-bromophenyl)methyl]-2-butyl-(731851-41-5)
• EPA Substance Registry System: 1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[(4-bromophenyl)methyl]-2-butyl-(731851-41-5)

Safety Data

• Hazardous Substances Data: 731851-41-5(Hazardous Substances Data)

Usage

Chemical structure

A complex organic compound with a spiro ring system, containing a diaza ring and a carbonyl group, as well as a 3-[(4-bromophenyl)methyl]-2-butylside chain.

Molecular weight

Approximately 364.28 g/mol (calculated from the molecular formula).

Functional groups

The compound contains a spiro ring system, a diaza ring (N-N), a carbonyl group (C=O), and a bromo-substituted phenyl group.

Potential applications

Due to its unique and complex structure, this chemical may have potential applications in pharmaceutical or chemical research.

Reactivity

The compound's properties and potential reactivity are not well-documented, so it is important to handle and use it with caution.

Further research

Additional research and analysis may be needed to fully understand the properties and potential uses of this chemical.

Safety precautions

As with any complex organic compound, it is essential to follow proper safety protocols when handling and using this chemical, including the use of appropriate personal protective equipment (PPE) and working in a well-ventilated area.

Upstream product

• 589-15-1 1-bromomethyl-4-bromobenzene 

Downstream Products

• 138402-10-5 trityl irbesartan 
• 138402-11-6 2-butyl-3-{4-[2-(1H-tetrazol-5-yl)phenyl]benzyl}-1,3-diazaspiro[4.4]non-1-en-4-one 

Relevant articles and documents

Synthesis and screening for acetylcholinesterase inhibitor activity of some novel 2-butyl-1,3-diaza-spiro[4,4]non-1-en-4-ones: Derivatives of irbesartan key intermediate

The association of bioactive nucleus with other pharmacological agents is hoped to improve the efficacy of the treatment by combining the effects of different pharmacological mechanisms of action. Keeping this in view, a series of 2-butyl-1,3-diaza-spiro[4,4]non-1-en-4-one derivatives have been synthesized by interaction of 2-butyl-1,3-diaza-spiro[4,4]non-1-en-4-one with different bioactive aralkyl halides in presence of powdered potassium carbonate by two different methods viz., conventional and microwave irradiation. The yields under conventional and microwave irradiation methods were in the range of 60-65% and 80-90%, respectively. The structure elucidation of the new compounds has been carried out with the help of elemental analysis and spectral data. All the synthesized compounds have been screened for their efficacy as acetylcholinesterase (AChE) inhibitor. AChE inhibitory activity study was carried out by using Ellman colorimetric assay with neostigmine as a reference standard against targets from different species, such as pure electric eel AChE, human serum AChE, and rat brain AChE. Among the compounds synthesized, compounds 5a, 5b, 5j showed good inhibition against AChE.

PROCESS FOR PREPARING IRBESARTAN

A process for preparing irbesartan comprises pentanoylation of cycloleucine in the presence of sodium hydroxide to form n-pentanoyl cycloleucine, condensing this product with 2-(4-aminomethyl phenyl) benzonitrile using dicyclohexyl carbodiimide and 1-hydroxy benzotriazole as a catalyst to form the 4-(?-N-pentanoyl amino) cyclopentamido methyl-2'-cyano biphenyl compound, and then cyclizing using trifluroacetic acid in the presence of an aromatic solvent to form cyano irbesartan. Cyano irbesartan is converted to irbesartan by reaction with tributyltin chloride and sodium azide in the presence of an aromatic solvent.